ArriVent BioPharma

NMQ:AVBP · US04272N1028

BiotechnologySmall

360° View

Value49

Price/Sales29

Price/Earnings75

Price/Book12

Dividend Yield—

Growth56

Revenue Growth—

Profit Growth31

Capital Growth100

TSR 52w44

Safety96

Leverage97

Liquidity47

Refinancing85

Combined74

Sentiment83

Analyst Opinions100

Pro Holdings65

Opinion Changes50

Market Pulse39

Profile

CountryUSA

IndustryBiotechnology

SizeSmall

TypePublic Company

ExchangeNASDAQGM

Founded2021

Employees66

Websitearrivent.com

ISINUS04272N1028

Last UpdateApr 2, 2026

Index & Theme

Chronic DiseasesImmunologyCentral Nervous SystemOncologyPulmonologyBiotechnologyLife SciencePharmaceutical

Description

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company. The company is dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cance…

Analysis

ArriVent BioPharma's 360° View rank of 89 places it among the strongest overall — better than 89% of its true peers.

It's growing solidly (56) and on the expensive side (49). On safety it is very well financed (96), and the market shows strongly positive sentiment (83). Taken together, its Combined rank of 74 reads as above its peer average.

360° rank · history

1007550250

2026

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare ArriVent BioPharma with its peers

Crescent Biopharma

NAQ:CBIO

CountryUSA

IndustryBiotechnology

SizeX-Small

Full Stock Analysis →

Sutro Biopharma

NMQ:STRO

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Day One Biopharmaceuticals

NSQ:DAWN

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Verastem

NAQ:VSTM

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Tyra Biosciences

NSQ:TYRA

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Prelude Therapeutics

NSQ:PRLD

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →